- First glioblastoma patient ever treated with Alpha DaRT® outside of the United States, and the first in Israel - performed at Hadassah University Medical Center in Jerusalem, one of the world’s...
- Following the pre-specified interim safety report and overwhelming demand from clinicians to treat patients as quickly as possible, Alpha Tau to resume recruitment immediately for the remaining seven...
- Joint partnership leverages Alpha Tau’s highly potent, localized alpha-radiation technology and Tolmar’s commercial leadership to transform the U.S. uro-oncology landscape - Collaboration...
- Results reinforce the potential feasibility and safety of Alpha DaRT as a one-time, minimally invasive intratumoral treatment that fits naturally into the patient journey - - Pooled analysis of...
Alpha Tau Medical (NASDAQ:DRTS) outlined a series of clinical and regulatory updates during the Lytham Partners Spring 2026 Investor Conference, with Raphi Levy of Alpha Tau telling investors the company’s...
- Groundbreaking interim results from U.S. REGAIN trial in recurrent glioblastoma demonstrate 100% local disease control, 67% complete response rate, and favorable safety profile - - Completion...
JERUSALEM, May 18, 2026 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT...
Barchart Research What to Expect from DRTS Earnings DRTS Generated May 15, 2026 Current Price $10.36 EPS Estimate $$-0.13 Consensus Rating Moderate Buy Average Move 4.28% Can Alpha Tau Medical Answer What...
Barchart Research What to Expect from DRTS Earnings DRTS Generated May 15, 2026 Current Price $10.36 EPS Estimate $$-0.13 Consensus Rating Moderate Buy Average Move 4.28% Can Alpha Tau Medical Answer What...
Barchart Research What to Expect from DRTS Earnings DRTS Generated May 15, 2026 Current Price $10.36 EPS Estimate $$-0.13 Consensus Rating Moderate Buy Average Move 4.28% Can Alpha Tau Medical Answer What...